1- Yang SZ, Tang Y, Zhang Y, Chen WG, Sun J, Chu TW. Prognostic factors and comparison of conservative treatment, percutaneous vertebroplasty, and open surgery in the treatment of spinal metastases from lung cancer. World Neurosurgery. 2017;108:163-175. [
Link] [
DOI:10.1016/j.wneu.2017.08.130]
Fermé Ch, Thomas J, Brice P, Casasnovas O, Vranovsky A, Bologna S, et al. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European organisation for research and treatment of cancer (EORTC)-groupe d'Étude des lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. European Journal of Cancer. 2017;81:45-55. [
Link] [
DOI:10.1016/j.ejca.2017.05.005]
Schild SE, Hillman SL, Tan AD, Ross HJ, McGinnis WL, Garces YA, et al. North central cancer treatment group. long-term results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (Alliance). Journal of Thoracic Oncology. 2017;12(4):697-703. [
Link] [
DOI:10.1016/j.jtho.2016.12.021]
Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XIII, on the criteria and kinetics associated with"curability" of experimental leukemria. Cancer Chemotherapy Report. 1964;35:1-111. [
Link]
Kohandel M, Sivaloganathan S, Oza A. Mathematical modeling of ovarian cancer treatments: Sequencing of surgery and chemotherapy. Journal of Theoretical Biology. 2006;242(1):62-68. [
Link] [
DOI:10.1016/j.jtbi.2006.02.001]
Simon R, Norton L. The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nature Clinical Practice Oncology. 2006;3(8):406-407. [
Link] [
DOI:10.1038/ncponc0560]
Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature. 1976;264(5586):542-545. [
Link] [
DOI:10.1038/264542a0]
De Pillis LG, Radunskaya A. The dynamics of an optimally controlled tumor model: A case study. Mathematical and Computer Modelling. 2003;37(11):1221-1244. [
Link] [
DOI:10.1016/S0895-7177(03)00133-X]
Ku-Carrillo RA, Delgadillo SE, Chen-Charpentier BM. A mathematical model for the effect of obesity on cancer growth and on the immune system response. Applied Mathematical Modelling. 2016;40(7-8):4908-4920. [
Link] [
DOI:10.1016/j.apm.2015.12.018]
Anderson ARA, Chaplain MAJ. Continuous and discrete mathematical models of tumor-induced angiogenesis. Bulletin of Mathematical Biology. 1998;60(5):857-899. [
Link] [
DOI:10.1006/bulm.1998.0042]
Pinho STR, Bacelar FS, Andrade RFS, Freedman HI. A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy. Nonlinear Analysis Real World Applications. 2013;14(1):815-828. [
Link] [
DOI:10.1016/j.nonrwa.2012.07.034]
Ku-Carrillo RA, Delgadillo-Aleman SE, Chen-Charpentier BM. Effects of the obesity on optimal control schedules of chemotherapy on a cancerous tumor. Journal of Computational and Applied Mathematics. 2017;309:603-610. [
Link] [
DOI:10.1016/j.cam.2016.05.010]
Khalili P, Vatankhah R, Taghvaei S. Optimal sliding mode control of drug delivery in cancerous tumour chemotherapy considering the obesity effects. IET Systems Biology. 2018;12(4):185-189. [
Link] [
DOI:10.1049/iet-syb.2017.0094]
Nasiri H, Akbarzadeh Kalat A. Adaptive fuzzy back-stepping control of drug dosage regimen in cancer treatment. Biomedical Signal Processing and Control. 2018;42:267-276. [
Link] [
DOI:10.1016/j.bspc.2018.02.001]
El-Garawany AH, Karar ME, El-Brawany MA. Embedded drug delivery controller for cancer chemotherapy under treatment constrains. 2017 Intl Conf on Advanced Control Circuits Systems (ACCS) Systems & 2017 Intl Conf on New Paradigms in Electronics & Information Technology (PEIT), 5-8 November, 2017, Alexandria, Egypt. Piscataway: IEEE; 2017. [
Link]
Wang LX. A course in fuzzy system and control. Upper Saddle River: Prentice Hall PTR; 1997. [
Link]
Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Research. 2000;60(7):1878-1886. [
Link]
